Fogg MH - Search Results

1

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.

Jankowski W, McGill J, Lagassé HAD, Surov S, Bembridge G, Bunce C, Cloake E, Fogg MH, Jankowska KI, Khan A, Marcotrigiano J, Ovanesov MV, Sauna ZE. Jankowski W, et al. Among authors: fogg mh. Blood Adv. 2019 Sep 10;3(17):2668-2678. doi: 10.1182/bloodadvances.2019000338. Blood Adv. 2019. PMID: 31506285 Free PMC article.

2

Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Ahmadi M, Bryson CJ, Cloake EA, Welch K, Filipe V, Romeijn S, Hawe A, Jiskoot W, Baker MP, Fogg MH. Ahmadi M, et al. Among authors: fogg mh. Pharm Res. 2015 Apr;32(4):1383-94. doi: 10.1007/s11095-014-1541-x. Pharm Res. 2015. PMID: 25319104

3

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics.

Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, Baker MP, Herskovitz J, Goletz TJ, Zhou L, Moxness M, Flynn GC, Narhi LO, Jawa V. Joubert MK, et al. PLoS One. 2016 Aug 5;11(8):e0159328. doi: 10.1371/journal.pone.0159328. eCollection 2016. PLoS One. 2016. PMID: 27494246 Free PMC article.

4

Subvisible Particles in Solutions of Remicade in Intravenous Saline Activate Immune System Pathways in In Vitro Human Cell Systems.

Pardeshi NN, Ahmadi M, Sierzputowska I, Fogg M, Baker M, Carpenter JF. Pardeshi NN, et al. J Pharm Sci. 2021 Aug;110(8):2894-2903. doi: 10.1016/j.xphs.2021.04.005. Epub 2021 Apr 14. J Pharm Sci. 2021. PMID: 33864780

5

A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.

Jones TD, Hearn AR, Holgate RGE, Kozub D, Fogg MH, Carr FJ, Baker MP, Lacadena J, Gehlsen KR. Jones TD, et al. Among authors: fogg mh. Protein Eng Des Sel. 2016 Nov 1;29(11):531-540. doi: 10.1093/protein/gzw045. Protein Eng Des Sel. 2016. PMID: 27578884 Free PMC article.

6

Identification of CD4+ T cell epitopes on the fusion (F) and attachment (G) proteins of bovine respiratory syncytial virus (BRSV).

Fogg MH, Parsons KR, Thomas LH, Taylor G. Fogg MH, et al. Vaccine. 2001 Apr 30;19(23-24):3226-40. doi: 10.1016/s0264-410x(01)00030-5. Vaccine. 2001. PMID: 11312019

7

An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.

Ohashi M, Fogg MH, Orlova N, Quink C, Wang F. Ohashi M, et al. Among authors: fogg mh. PLoS Pathog. 2012 Dec;8(12):e1003095. doi: 10.1371/journal.ppat.1003095. Epub 2012 Dec 27. PLoS Pathog. 2012. PMID: 23300447 Free PMC article.

8

Reduced prevalence of Epstein-Barr virus-related lymphocryptovirus infection in sera from a new world primate.

Fogg MH, Carville A, Cameron J, Quink C, Wang F. Fogg MH, et al. J Virol. 2005 Aug;79(15):10069-72. doi: 10.1128/JVI.79.15.10069-10072.2005. J Virol. 2005. PMID: 16014968 Free PMC article.

9

The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue.

Fogg MH, Kaur A, Cho YG, Wang F. Fogg MH, et al. J Virol. 2005 Oct;79(20):12681-91. doi: 10.1128/JVI.79.20.12681-12691.2005. J Virol. 2005. PMID: 16188971 Free PMC article.

10

Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.

Orlova N, Fogg MH, Carville A, Wang F. Orlova N, et al. Among authors: fogg mh. Clin Vaccine Immunol. 2011 Sep;18(9):1427-34. doi: 10.1128/CVI.05126-11. Epub 2011 Jul 6. Clin Vaccine Immunol. 2011. PMID: 21734064 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters